Apellis Pharmaceuticals, Inc.

NasdaqGS:APLS Stock Report

Market Cap: US$2.4b

Apellis Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:APLS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
11 Feb 26SellUS$8,153Mark DelongIndividual368US$22.15
22 Jan 26SellUS$591,845Cedric FrancoisIndividual27,192US$21.77
22 Jan 26SellUS$44,924James ChopasIndividual2,064US$21.77
22 Jan 26SellUS$168,138Nur NicholsonIndividual7,725US$21.77
22 Jan 26SellUS$170,467David WatsonIndividual7,832US$21.77
22 Jan 26SellUS$223,901Timothy SullivanIndividual10,287US$21.77
22 Jan 26SellUS$129,025Pascal DeschateletsIndividual5,928US$21.77
22 Jan 26SellUS$60,878Caroline BaumalIndividual2,797US$21.77
22 Jan 26SellUS$73,371Mark DelongIndividual3,371US$21.77
20 Jan 26SellUS$26,404Mark DelongIndividual1,334US$19.79
20 Jan 26SellUS$48,987David WatsonIndividual2,475US$19.79
20 Jan 26SellUS$43,604Nur NicholsonIndividual2,203US$19.79
20 Jan 26SellUS$161,946Cedric FrancoisIndividual8,182US$19.79
20 Jan 26SellUS$57,241Timothy SullivanIndividual2,892US$19.79
20 Jan 26SellUS$17,992Pascal DeschateletsIndividual909US$19.79
20 Jan 26SellUS$37,250Caroline BaumalIndividual1,882US$19.79
20 Jan 26SellUS$14,370James ChopasIndividual726US$19.79
13 Jan 26SellUS$128,242David WatsonIndividual5,780US$22.19
13 Jan 26SellUS$39,493Mark DelongIndividual1,780US$22.19
13 Jan 26SellUS$85,554Timothy SullivanIndividual3,856US$22.19
13 Jan 26SellUS$225,999Cedric FrancoisIndividual10,186US$22.19
13 Jan 26SellUS$58,086Nur NicholsonIndividual2,618US$22.19
13 Jan 26SellUS$19,369James ChopasIndividual873US$22.19
13 Jan 26SellUS$50,520Pascal DeschateletsIndividual2,277US$22.19
05 Jan 26SellUS$77,097Caroline BaumalIndividual3,020US$25.53
15 Sep 25SellUS$4,572James ChopasIndividual189US$24.19
10 Sep 25SellUS$523,400David WatsonIndividual20,000US$26.17
08 Sep 25SellUS$278,300Timothy SullivanIndividual10,000US$27.83
02 Sep 25SellUS$15,386James ChopasIndividual548US$28.08
28 Aug 25SellUS$6,352,743Cedric FrancoisIndividual225,000US$28.39
17 Mar 25SellUS$4,543James ChopasIndividual183US$24.82

Insider Trading Volume

Insider Buying: APLS insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of APLS?
Owner TypeNumber of SharesOwnership Percentage
State or Government45,1700.0297%
Individual Insiders4,093,8932.69%
Hedge Funds19,888,98613.1%
VC/PE Firms20,556,34213.5%
Institutions107,347,29770.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 96.2% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.4%
BlackRock, Inc.
13,227,713US$250.5m111%no data
10%
The Morningside Group Limited
12,806,342US$242.6m0%10.83%
9.95%
Wellington Management Group LLP
12,721,352US$240.9m36.9%0.04%
9.56%
Avoro Capital Advisors LLC
12,222,222US$231.5m0%2.46%
8.35%
The Vanguard Group, Inc.
10,674,865US$202.2m6.88%no data
7.01%
Morgan Stanley
8,960,757US$169.7m-4.46%0.02%
6.06%
Deep Track Capital, LP
7,750,000US$146.8m-3.13%3.25%
6%
RTW Investments, LP
7,666,764US$145.2m0%1.65%
3.61%
State Street Global Advisors, Inc.
4,613,446US$87.4m14.3%no data
3.41%
UBS Asset Management AG
4,365,110US$82.7m21.3%0.01%
3.24%
Suvretta Capital Management, LLC
4,139,426US$78.4m43.8%1.89%
2.9%
Polar Capital Holdings Plc
3,706,510US$70.2m39.9%0.2%
2.02%
Artal Group S.A.
2,578,396US$48.8m0%1.02%
1.9%
OrbiMed Advisors LLC
2,429,868US$46.0m4.58%0.68%
1.74%
AQR Capital Management, LLC
2,228,562US$42.2m-49.2%0.02%
1.58%
Geode Capital Management, LLC
2,025,669US$38.4m-2.28%no data
1.18%
Jennison Associates LLC
1,504,299US$28.5m-65.4%0.02%
1.15%
Cedric Francois
1,471,787US$27.9m2.83%no data
1.07%
Deutsche Asset & Wealth Management
1,364,125US$25.8m-8.16%0.01%
0.94%
Norges Bank Investment Management
1,198,444US$22.7m-49.4%no data
0.92%
Hudson Bay Capital Management LP
1,179,828US$22.3m182%0.15%
0.88%
Pascal Deschatelets
1,129,347US$21.4m0.69%no data
0.84%
The Bank of Nova Scotia
1,070,141US$20.3m-26.5%0.03%
0.78%
Marshall Wace LLP
990,848US$18.8m150%0.02%
0.74%
Los Angeles Capital Management LLC
951,716US$18.0m53.3%0.06%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/16 09:58
End of Day Share Price 2026/03/13 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apellis Pharmaceuticals, Inc. is covered by 34 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael UlzBaird
Colleen KusyBaird
Eliana MerleBarclays